Pharmaco-metabonomic phenotyping and personalized drug treatment
By T. A. Clayton, John C. Lindon, Olivier Cloarec, H. Antti, C. Charuel, G. Hanton, J. Provost, J. L. Net, D. Baker, R. Walley and 2 more. Nature, 2006
816 citations recorded by the source corpus.
Subfields: Molecular Biology, Pharmacology, Physiology
View Paper: https://www.semanticscholar.org/paper/4b0d403aeeb0807939ccd52309b4864758d56353
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Jeremy K. Nicholson
- Ian A. Wilson
- Edward C. Holmes
- John C. Lindon
- James Kinross
- Ara Darzi
- David S. Wishart
- Richard M. Weinshilboum
In Pharmacology
In Physiology
Citations in the corpus
- Big data: the next frontier for innovation in therapeutics and healthcare (2014, background): “Similarly, Clayton et al. developed personalized pharmacometabolomics, where pre-dose urinary metabolite profiles are predictive of drug-induced hepatocellular toxicity [17] .”
- Metabolomics: a global biochemical approach to drug response and disease. (2008, methodology): “A higher predrug urinary taurine level was associated with more class 1 than class 3 hepatic histology, whereas higher combined predrug concentrations of TMAO and betaine were associated with more class 3 than class 1 histology (38).”
- Gut microbiome-host interactions in health and disease (2011, background): “The gut microbiota also influence drug metabolism and toxicity [11], dietary calorific bioavailability [12], immune system conditioning and response [13], and post-surgical recovery [14].”
- Metabolic phenotyping in health and disease. (2008, background): “We have demonstrated a pharmacometabonomic approach to predicting the interventional outcome of drugs based on mathematical models of pre-dose metabolic profiles (Clayton et al., 2006).”
- Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism (2009, methodology): “Recognizing this important limitation of pharmacogenomics, a different approach to personalized drug treatment has recently been proposed wherein predose metabolite profiling would instead be used to predict a subject’s responses to potential drug interventions (9).”